Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.
|Published (Last):||1 June 2007|
|PDF File Size:||19.72 Mb|
|ePub File Size:||11.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
Advances in the diagnosis, pathogenesis and treatment of CIDP
This paper has been referenced on Twitter 1 time over the past 90 days. Bertsias Current opinion in rheumatology An update on the management of chronic inflammatory demyelinating polyneuropathy.
An open label clinical trial of complement inhibition in multifocal motor neuropathy. Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies. Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have been reached for research or clinical practice.
Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic.
MRI assessment including apparent diffusion coefficient. Citations Publications citing this paper. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions. Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.
Armati Journal of the peripheral nervous system: Topics Discussed in This Inn.
Brannagan Journal of the peripheral nervous system: Kenneth Craig Gorson Therapeutic advances in neurological disorders Chronic inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune neuropathy. Commonly used immunosuppressive drugs offer minimal benefit, necessitating the rteatment of new therapies for treatment-refractory patients. Dalakas The Lancet Neurology BoumpasGeorge K.
Showing of 60 extracted citations. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Skip to search form Skip to main content. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy. From This Paper Figures, tables, and topics from this paper. Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on treatmeng many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached for research or clinical practice.
Advances in the diagnosis, pathogenesis and treatment of CIDP – Semantic Scholar
Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. References Publications referenced by this paper. John David PollardPatricia J.
Current diagnosis of CIDP: Showing of references. Pathogenesis and treatment of CNS lupus.